tion after TM in European patients with T2DM [3] . In Japanese patients with T2DM, Lee et al. [4] , Kozawa et al. [5] and Yabe et al. [6] reported the response of plasma active GIP after ingestion of TM was similar between Japanese patients with T2DM and controls. Furthermore, Yabe et al. reported that total GIP secretion in patients with T2DM was also similar to controls [6] and they [7] reported that postprandial GIP levels in drug-naïve patients with T2DM but not in sulfonylurea (SU)-treated patients was positively correlated with increments of plasma glucose (PG) using the area under the curve (AUC). These patients were also negatively correlated with fasting serum immunoreactive insulin (s-IRI), homeostasis model assessments for beta-cell function (HOMA-β), and secretory units in transplantation (SUIT) [8] . SU has little effect on GIP secretion. Further, Nagai et al. [9] reported that GIP secretion in Japanese patients with T1DM was affected by administration of α-glucosidase inhibitor. Therefore, this study tions of long-acting insulin analogues prior to sleep, and bolus subcutaneous injections of rapid-acting insulin analogues in MDI, bolus and basal administration of rapid-acting insulin analogues in CSII, or subcutaneous injections of mixed insulin analogues twice a day. Additionally, some patients were treated with anti-hyperlipidemic or anti-hypertensive drugs.
None of the participants had a history of gastrointestinal disease, anemia, or impaired liver function and none were receiving any other medications.
Written informed consent to participate in the present study was obtained from all subjects. This study was performed in accordance with the Declaration of Helsinki and with the approval of our hospital ethics committees.
Study design
The study design has been previously reported [10, 11] . Briefly, subjects were studied at 9:00 a.m., following a 10-hour fast. The TM (560 kcal) comprised 17% protein, 23% fat, and 60% carbohydrate [10, 11] . During the study, patients were stopped from taking their oral medications but received subcutaneous injections of insulin analogues.
Insulin resistance and beta-cell function were assessed using homeostasis model assessments for insulin resistance (HOMA-R) and HOMA-β (%), which was calculated by the equations reported previously [16] . SUIT was calculated by the formula: 250 x fasting s-CPR / (fasting PG-3.43) as previously described [8] . This has been developed as an index of beta-cell function using serum immunoreactive C-peptide (s-CPR) in the islettransplanted patients with T1DM. The insulinogenic index during the post-ingestion of TM was used as a marker of early-phase insulin secretion. The index was calculated by the ratio of change in s-IRI levels (µU/mL) to that of PG levels (mg/dL) from baseline to 30 minutes after ingestion of TM, as previously described [4] .
Immediately before, as well as at 30 and 60 minutes post TM ingestion, blood samples were collected in icecooled tubes from the inserted cannula. Blood samples were separated by centrifugation at 4°C for later determination of PG, s-IRI, s-CPR, p-total GIP levels, and HbA1c levels. Blood samples for assessment of total GIP and glucose were collected in ice-cooled vacutainers containing EDTA with 10 μL DPP-IV inhibitor (diprotin) per mL of blood and in vacutainers containing NaF, respectively [10, 11] .
The AUC of PG, s-IRI, s-CPR, and p-total GIP levreexamined whether GIP secretion in diabetic Japanese patients is influenced by gender, age, type of disease, duration of disease, presence of vascular complications, obesity, administration of various drugs for diseases, or other various factors. We examined total GIP secretion in response to TM be similar to the one used by Vilsbøll et al. [2] in Japanese patients with various BMIs and clinical characteristics.
materials and methods
Forty-four Japanese patients with T1DM (group 1, n = 15) or T2DM (group 2, n = 29) who had various BMIs, were not hypoglycemic, and regularly visited our clinics were studied. Groups 1 and 2 included the patients reported previously [10, 11] . Based on criteria of the Japan Society for Study of Obesity [12] , the patients were divided into obese (BMI ≥ 25 kg/m 2 ) and non-obese (BMI < 25 kg/m 2 ). Diabetes was diagnosed according to the World Health Organization criteria [13] using an HbA1c value of ≥ 6.5% (NGSP; National Glycohemoglobin Standardization Program) [14, 15] (Table 1) .
Demographic characteristics of the participants are presented in Table 1 . The average duration of diabetes from initial discovery was approximately more than 10 years. Therefore, some patients had microvascular disturbances including retinopathy, nephropathy, or peripheral neuropathy, as well as macrovascular disturbances including asymptomatic coronary heart or cerebral vascular disease. The presence of retinopathy was examined by an ophthalmologist, while that of nephropathy and neuropathy was ascertained by means of albuminuria and Achilles' tendon reflex, respectively. Macrovascular complications were defined according to past medical history.
Diabetic patients had been treated with various therapies. Patients with non-insulin requiring T2DM who had no serum antibody for insulin were treated with diet, exercise, and/or oral pharmacotherapy for hyperglycemia. Oral pharmacotherapy consisted of α-glycosidase inhibitors (α-GI), SU, biguanide (BG), thiazolidinedione (TZD), or combinations of these agents (Table  1) . Meanwhile, patients with insulin requiring DM for hyperglycemia were treated with insulin analogues using multiple daily injections (MDI) [10] , of subcutaneous insulin infusions (CSII) [10] or twice-daily injections. Insulin therapy consisted of subcutaneous injec-
Assay Methods
All assay methods except p-total GIP have been previously described [10, 11] . Briefly, HbA1c (JDS) as a glycemic control was measured using high-performance liquid chromatography (HPLC) and the value was expressed as NGSP equivalence, as per guidelines of the Committee on the Classification and Diagnostic Criteria of DM [14, 15] . PG was measured with the els at 0 and 30 minutes after ingestion of TM were calculated as reported previously [2] . The AUC of GIP was presented as the early-phase based on that the AUC were divided into two responses, early-phase (AUC of 0-30 minutes after ingestion of TM) and late-phase (AUC of 30-180 minutes after ingestion of TM) [2, 6] . Data are expressed as means ± SD. Each value was collected in the morning after a 10-hour fast. HOMA-R = fasting immunoreactive insulin (IRI) (µU/mL) × fasting plasma glucose (PG) (mg/dL)/405, HOMA-β = fasting IRI x 360 / (fasting PG -63) and SUIT = 250 x fasting serum immunoreactive C-peptide / (fasting PG -3.43). NGSP, national glycohemoglobin standard program; HOMA-R, homeostasis model assessment-insulin resistance; HOMA-β, homeostasis model assessment-beta cell function; SUIT; secretory units in transplantation; NDR, nondiabetic retinopathy; SDR, simple diabetic retinopathy; PPDR, pre-proliferative retinopathy; PDR, proliferative retinopathy; Normo, normoalbuminuria; Micro, microalbuminuria; Macro, macroalbuminuria;α-GI, alpha-glucosidase inhibitor; BG, biguanide; TZD, thiazolizinedione; SU, sulfonylurea. Differences between the means in two groups were statistically evaluated by chi square analysis or unpaired t tests with or without Welch's correction. Two-tailed values of p < 0.05 were defined as statistically significant (****p < 0.0001, ***p < 0.001, and **p < 0.01 vs. Group 2).
analyzed using a Pearson correlation analysis with a linear least squares method. Two-tailed values of p < 0.05 were considered to be statistically significant. Analysis was performed using GraphPad Prism version 5.04 and the Statistical Package for the Biosciences for Windows (ComWorks Co, Tokyo, Japan).
results
There were more patients in group 2 than group 1 at baseline. Means of age, BMI, HbA1c, PG, s-CPR, SUIT, and p-total GIP were significantly lower in group 1 than in group 2, whereas means of s-IRI and HOMA-R were significantly higher in group 1 than in group 2 (Table 1) . Furthermore, means of HOMA-β, s-CPR and SUIT were significantly (p<0.01) higher in patients without insulin requiring T2DM and without presence of human insulin antibody (n=17) than in patients with insulin requiring T2DM (n=12) (data were not shown). There were no significant differences between groups in other variables ( Table 1) .
The mean duration of disease was significantly higher in group 1 than in group 2. In group 1, there was no patient with macrovascular disturbance and only one patient with microvascular disturbance as microalbuminuria, whereas in group 2 there were few patients with macrovascular disturbance, although a large number of patients with microvascular disturbances were observed ( Table 1 ). The incidence of microangiopathy including retinopathy and nephropathy was significantly lower in group 1 than in group 2 ( Table 1) . No other significant differences between groups in the incidences of micro-and macro-vascular complications were observed. In group 1, no patients were treated with oral drugs for hyperglycemia, whereas in group 2, around half of the patients had been treated with insulin therapy combined with oral drugs for hyperglycemia, although most patients had been treated with a combination of oral α-G, BG, TZD, and/or SU (Table 1) and there were only four drug-naïve patients. There were no significant differences in the frequency of other pharmacotherapy administrations between groups ( Table 1) .
Means of peaked PG and p-total GIP levels were shown at 60 minutes after ingestion of TM in groups 1 and 2 ( Figs. 1 and 2 ). Mean of AUC in PG, s-CPR, or p-total GIP was also significantly (p < 0.001) lower in group 1 than in group 2 (data were not shown).
The AUC of total GIP was not significantly (p = 0.51 oxidase method. S-IRI and s-CPR, markers for endogenous insulin secretion were measured using two-site sandwich immunoassay kits. The intra-and inter-assay coefficients of variation for these assays were both < 5% [10, 11] . As previously reported [9, 17, 18] , p-total GIP was measured at SRL, Inc. (Tokyo, Japan) with two-site sandwich immunoassay using a total GIP ELISA kit (Millipore Corp, Billerica, MA, USA) in unextracted samples as based on approval of the Japan Diabetes Society and the Japan Association for Diabetes Education and Care Committee for Standardized Incretin Measurement [7, 19] . The antibody provided with the kit specifically recognizes human GIP (1-42) and GIP (3-42), but not other forms of oxyntomodulin, GLP-1, or GLP-2. The limit of detection for this assay is < 1.6 pmol/L. The intra-and inter-assay coefficients of variation were both < 5%.
Statistical Methods
Results are expressed as means ± SD. Differences between groups in baseline variables were evaluated statistically by chi square or unpaired t tests with or without Welch's correction [10, 11] . The same method was used to determine how the response was affected by ingestion of the TM [10, 11] .
A logistic multiple regression analysis was used to identify independent predictors for early-phase of p-total GIP AUC in groups. Age, BMI, HbA1c, fasting PG, fasting s-CPR, or/and SUIT and duration of disease were included as independent variables in each model. Additionally, sex, chronic complications for microangiopathy or macroangiopathy, oral drugs and insulin therapy for hyperglycemia, and lipid-lowering or hypertensive drugs were added as independent predictors in logistic multiple regression analyses. Sex, use of oral drugs or insulin therapy for hyperglycemia, use of lipid-lowering drugs, and use of hypertensive drugs were coded dichotomously ("0" and "1"). No microangiopathy was coded as "0", simple retinopathy, microalbuminuria, or peripheral neuropathy as "1", pre-proliferative retinopathy or macroalbuminuria as "2", and proliferative retinopathy as "3". Furthermore, no macroangiopathy was coded as "0" and any asymptomatic coronary heart disease or asymptomatic cerebral vascular disease coded as "1".
The correlation coefficient (r) and the direction and magnitude of correlation between the AUC of p-total GIP and the AUC of PG or BMI were also statistically pertensive drugs by a logistic regression analysis (Table  2) , but it was tended to have a negative correlation with BMI by a Pearson correlation analysis with a linear least squares method (Fig. 3A) . The correlation of the AUC in total GIP and s-IRI was not analyzed. In group 2, the AUC of total GIP was significantly (p<0.03) correlated with BMI in the patients with non-obesity as well as obesity by a Pearson correlation analysis with a and p = 0.64) correlated with the AUC of PG in groups 1 and 2 by a Pearson correlation analysis with a linear least squares method, respectively (data were not shown). Therefore, when the AUC of PG and related factors were excluded from the model, in group 1 mean the AUC of p-total GIP was not significantly correlated with age, sex, BMI, HbA1c, fasting PG, fasting s-CPR, SUIT, duration of disease, microangiopathy, or anti-hy- (Tables 2 and 3 ).
linear least squares method (data were not shown) and was positively correlated with only BMI in all patients with T2DM significantly by a logistic regression analysis (Table 3) and by a Pearson correlation analysis with a linear least squares method (Fig. 3B) . The AUC of total GIP in the type 2 diabetic patients without requir- Fig. 3 Relationship between the area under the curve (AUC) of plasma total GIP (p-total GIP) levels in the early-phase after the ingestion of breakfast test meals (y-axis) and BMI (x-axis) in 15 Japanese patients with type 1 diabetes mellitus (A) and 29 Japanese patients with type 2 diabetes mellitus (B). The test meal consisted of 560 kcal (17% protein, 23% fats, and 60% carbohydrate). Prior to testing, all patients underwent a 10-hour overnight fast. During the study, patients stopped all oral medications, but received subcutaneous injections of insulin analogues. The AUC was calculated using p-total GIP levels at baseline and at 30 minutes after the test meal. The correlation coefficient (r) and the direction and magnitude of correlation in samples were statistically analyzed using Pearson correlation analysis with the linear least squares method. Two-tailed values of p < 0.05 were considered to be statistically significant. Although it was unclear that the patients in this study had autonomic neuropathy, some may have, since autonomic neuropathy is related to duration of disease. However, the patients did not complain of clinical symptoms such as orthostatic hypotension, awareness hypoglycemia, or other related disturbances. Further, Toft-Nielsen et al. reported that there was no significant association between p-total GIP secretion and autonomic neuropathy in diabetic patients [21] . The third limitation is that we examined GIP secretion in early-phase after ingestion of TM, but not in latephase [2, 6] . Vilsbøll et al. reported the AUC in both phases are important since the early response (AUC, 0 to 30 min) after different TMs was same in diabetic patients and controls, but the late response (AUC, 30 to 180 min) was significantly lower in diabetic patients with low calorie TM (260 kcal) than in those with high calorie TM (520 kcal), although the composition of two TMs was same (19% protein, 33% fat and 48% carbohydrate) [2] .
Plasma extraction is a prerequisite for specifically measuring intact forms of incretin hormones. However, plasma extraction showed little effect on levels of total GIP [7] and therefore is not required for
Discussion
The patients in the present study had T1DM and T2DM, and were varied in their BMIs. The majority of patients had been suffering from diabetes for a prolonged period, had various related complications, and had received various types of pharmacotherapy, but no incretin-related medications for hyperglycemia and other diseases. We examined factors that may be related to p-total GIP secretions in these patients.
The first limitation of this study was that p-total GIP levels were not measured in control subjects. Therefore, we refer to levels of GIP secretion in controls from other studies [17, 18] , which reported that basal and postprandial p-total GIP levels measured using the same kits as in this study in type 2 diabetics were not significantly different from those in controls. However, total caloric contents and ratio of nutrition used as the TM in the studies were varied.
The second limitation was that we did not examine the presence of autonomic neuropathy using laboratory tests as previously reported methods [2, 20, 21] . Autonomic neuropathy may impair the incretin effect in DM through interference with GIP secretion [20] . [2] . NGSP, national glycohemoglobin standard program. Two-tailed values of p < 0.05 were defined as statistically significant.
In patients with T2DM, this study showed the AUC of GIP was not significantly correlated to not only fasting s-IRI, HOMA-β, and SUIT but also age, gender, HbA1c, fasting PG, fasting s-CPR, durations of disease, micro-or macro-vascular disturbances, oral drugs or insulin therapy for hyperglycemia, and oral drugs for other diseases. However, it was positively associated with only BMI in the patients with T2DM. Yabe et al. reported there was no correlation of p-total GIP secretion and BMI in drug-naïve patients [7] . Although this study could not be analyzed it using the total-phase AUC of total GIP after TM in drug-naïve patients as they were few, the difference may be partially explained by the findings that their study did not include diabetic patients with obese and there was not much variation in BMI (mean BMI 22.9 kg/m 2 ) [7] . The positive association between early-phase GIP secretion and BMI in the all patients may be explained by the hypothesis of Marks [26] and Zhou et al. [27] , who suggest that GIP might function as an obesity-promoting hormone and as a fat accumulation hormone, respectively. Additionally, Miyawaki et al. [28] showed that GIP-receptor knockout mice gained less weight than normal mice when treated with a high-fat diet. Thus, GIP secretion not only mediates early insulin secretion by acting on pancreatic beta-cells, but may also be related to obesity [23, 29] . Indeed, as suggested in prior reviews [23, 30, 31] , hypersecretion of early-phase GIP in diabetic Japanese patients with T2DM may be related to obesity.
Furthermore, Yabe et al. [7] reported that the postprandial GIP secretion in drug-naïve patients was negatively correlated with fasting s-IRI, HOMA-β, and SUIT. Also, Harada et al. [18] reported that the postprandial GIP secretion in healthy non-obese Japanese subjects was positively correlated with insulinogenic index. Insulinogenic index is different in the healthy controls and the patients with TM1 or TM2 differed pathophysiology. Moreover, s-IRI, HOMA-β levels and insulinogenic index determined by the immunoreactive methods are affected by the various factors. Therefore, we examined the predictors in type 2 diabetic patients without influence of such various factors since drug-naïve patients were few. The analyses also revealed no significant association between the AUC of GIP in early-phase and s-IRI, HOMA-β, SUIT or insulinogenic index. The discrepancy may be explained by the evidences that this study used the AUC of total GIP in early-phase after TM, whereas they used the AUC of total GIP in total-phase, and that there was differmeasuring levels of total GIP as approved by the Japan Diabetes Society and the Japan Association for Diabetes Education and Care Committee [19] . In this study, the postprandial secretion and AUC increments of GIP in unextracted samples from the diabetic patients with or without endogenous insulin secretion increased immediately after ingestion of the TM, respectively, which were similar to the results reported by Yabe et al. [7] .
In patients with T1DM, who had no endogenous insulin secretion and a different pathophysiology from T2DM, means of basal and the AUC of p-total GIP were lower than those in patients with T2DM, which differences were accompanied with age, BMI, HbA1c, PG, s-CPR, SUIT, duration of disease, method of therapy or frequency of microangiopathy. The AUC of p-total GIP was not significantly correlated with them. However, Harada et al. [18] reported that GIP secretion estimated by p-total GIP using the same kit as this study after a 75 g oral glucose tolerance test (OGTT) is positively correlated with BMI in healthy non-obese Japanese subjects. In this study, all patients had T1DM and had been treated with insulin therapy, and the postprandial GIP was dramatically increased. The postprandial GIP secretion in Europeans patients with T1DM was not impaired in comparisons with control [2, 22] and in Japanese patients with T1DM was also intact and decreased by administration of α-glycosidase inhibitor via K type cell [9] . Accordingly, the reasons of discrepancy in the GIP secretion in patients with T1DM and T2DM, and in the correlation of the AUC of total GIP and BMI in patients with T1DM and healthy control [18] may be due to different types of diabetes and/or amount of exogenous insulin [23] , and to different method of evaluation for the AUC of total GIP, respectively. In amount of exogenous insulin, however, it is impossible to estimate the effective amount in patients with T1DM accurately because s-IRI values determined by immunoreactive methods are influenced by various kinds of insulin, the presence of antibodies for insulin, or other factors. Their study used 75 g of glucose in an OGTT as TM, whereas we used various nutrients including fat in TM. We also estimated total GIP secretion in the early-phase, whereas they did it for the total-phase. Anyway, the tendency of negative correlation with the AUC of p-total GIP and BMI in this study may be a reasonable response as shown in obesity patients with normal glucose tolerance [25] . Thus, obesity in patients with T1DM may be due to other factors but not GIP. The precise reason for the difference remains unresolved.
Vilsbøll et al. reported that GIP secretion in Europeans with T2DM was normal [2] , whereas Škrha et al. reported that post-TM GIP secretion in Europeans with T2DM was impaired [3] . We could not identify factors that may explain the disparate findings of these two studies. The patients in the study by Vilsbøll et al. [2] had no autonomic neuropathy owing to disturbance of digestive systems, whereas it is unknown whether the patients in the Škrha et al. study [3] had such autonomic neuropathy. Vilsbøll et al. [2] used an ELISA kit developed by their own group, whereas Škrha et al. [3] used an RIA kit developed by Phoenix Pharmaceuticals Inc. (Burlingame, CA, USA). In the Škrha et al., study, patients were treated with BG alone, whereas patients in the Vilsbøll et al. study were treated with diet, BG, and/ or SU. The total calories of the TM were 445 kcal in the former study and 520 kcal in the latter. However, it is unlikely that any of these factors can explain the different findings [2, 23] . Škrha et al. [3] reported that mean BMI in type 2 diabetics was significantly lower than that in controls (29. ). In addition, neither study had patients with variance in BMI levels. Therefore, the disparate results of these two studies may be explained by the difference in BMI between patients and controls in the one study, but not in the other. Otherwise, the AUC of GIP levels may be related to insulin secretion. In fact, the mean AUC of GIP/s-IRI in patients by the Škrha et al. [3] was higher than that in controls as those shown in patients by Vilsbøll et al. [2] , indicating that there might be no impairment of postprandial GIP secretion in the patients.
The present study demonstrated that the early-phase AUC of p-total GIP following ingestion of a TM was positively related to BMI level in patients with T2DM who had various BMIs, but not with T1DM. The earlyphase AUC of p-total GIP was not influenced by gender, age, glycemic control, endogenous insulin secretion, duration of disease, a presence of complications, treatment with oral drugs for hyperglycemia, or treatment with oral drugs for other diseases. However, GIP secretion was found to increase dramatically with plasma glucose after ingestion of TM in all patients. In the future, it will be important to clarify whether visceral or subcutaneous adipose tissue is associated with GIP secretion in diabetic patients.
In conclusion, our results indicate that postprandial GIP secretion in early-phase after TM in Japanese ence in degree of glucose tolerance in the studies since the insulinotropic effect of GIP could be largely attenuated by T2DM in the drug-naïve Japanese patients with moderate to severe degree [23] . Probably, the degree in drug-naïve Japanese patients by Yabe et al. [7] may be mild. It is reported that the attenuated insulinotropic function of GIP in European patients with T2DM may be considered largely due to hyperglycemia, but not due to T2DM, because that GIP's insulinotropic function has been restored by normalized glucose levels by insulin therapy [32] . However, the GIP secretion was merely partially restored using exogenous insulin and the patients examined were European rather than Japanese [32] . Therefore, T2DM itself in Japanese patients may be a factor for the attenuated insulinotropic action. Nevertheless, it remains to be determined how molecular mechanisms underlying the impaired insulinotropic action of GIP in patients with diabetes mellitus is involved [23] .
Regarding chronic complications, there was no significant influence of microangiopathy or macroangiopathy on GIP secretion in early-phase in any of the diabetic patients. To the best of our knowledge, this is the first report to suggest that there was no significant influence of GIP secretion in early-phase for micro-or macro-angiopathy. Prospective controlled clinical trials are required to establish these relationships in diabetic patients.
Although Yabe et al. recently reported that SU has little effect on GIP secretion [7] , SU has been implicated in the secretion of GIP [32] . In addition, BG has been shown to affect GLP-1 secretion, but its effects on GIP secretion are largely unknown. Accordingly, we wanted to compare the AUC of s-total GIP in drug-naïve, SU alone-or BG alone-treated patients. However, as there were very few of the patients available, we were not able to analyze the differences. In this study, there was no significant effect of oral drugs or insulin therapy for hyperglycemia on the GIP secretion in early-phase in all patients with T2DM, although we were not able to analyze the effect of insulin therapy on the GIP secretion in patients with T1DM. Previously, we reported that plasma active GLP-1 levels were influenced by bolus injections of insulin in patients with T1DM [10] and Creutzfeldt et al. reported a negativefeedback control between insulin and GIP secretions [33] . This issue needs to be resolved in the future. Other lipid-lowering and hypertensive medications did not influence GIP secretion.
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